Evidence map›Paper›PMID 29581845›Full record

ArticleOncotarget2018

Geraldine H Chang, Razelle Kurzrock, Lisa Tran, Maria Schwaederle, Carl K Hoh

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Standardized uptake value (SUVCancer biology & therapy · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Geraldine H ChangDepartment of Radiology, Nuclear Medicine UC San Diego Health, San Diego, California, USA.
Razelle KurzrockCenter for Personalized Cancer Therapy, UCSD Moores Cancer Center, La Jolla, California, USA.
Lisa TranCenter for Personalized Cancer Therapy, UCSD Moores Cancer Center, La Jolla, California, USA.
Maria SchwaederleCenter for Personalized Cancer Therapy, UCSD Moores Cancer Center, La Jolla, California, USA.
Carl K HohDepartment of Radiology, Nuclear Medicine UC San Diego Health, San Diego, California, USA.
Moores Cancer CenterUC San Diego Health System · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundOur study explored the relationship between the molecular changes in cancer and the maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) with [

resultsA higher SUVmax correlated with

conclusionsA higher SUVmax on

methodsOverall, 176 patients with diverse cancers had a tumor biopsy within 6 months after a PET/CT image for SUVmax measurement. The biopsy was interrogated by next generation sequencing (182 to 315 genes).

Indexed as

personalized cancer therapyPET/CTSUVmaxTP53

Identifiers

PMID29581845
PMCPMC5865671
OpenAlexW2793016013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.